Earlier this month, the U.S. Department of Transportation (DOT) issued a final rule that expands the Department’s current drug testing panel to include certain semi-synthetic opioids (i.e., hydrocodone, hydromorphone, oxymorphone, and oxycodone) in its drug testing panel for DOT-regulated industries.
This is a direct effort to enhance safety, prevent opioid abuse, and combat the nation’s growing opioid epidemic. The DOT currently requires drug testing of safety-sensitive employees in the transportation industries, which includes: CDL holders who operate Commercial Motor Vehicles, 26,001 lbs. GVWR. or greater, operate a vehicle that carries 16 passengers or more including the driver, or are required to display a DOT placard in the transportation of hazardous material.
For more details review the Part 40 Final Rule – DOT Summary of Changes located on the Office of Drug and Alcohol Policy and Compliance (ODAPC) website, or contact ISRI’s Transportation Safety Director Commodor Hall.